Home / Expertise / Life Sciences & Healthcare
laboratory shelfs with bottles and vials

Life Sciences & Healthcare

Germany

The CMS Life Sciences und Healthcare Sector Group is made up of over 50 lawyers across Europe, many of whom have specialised in the Life Sciences und Healthcare industry for several years.

The essence of the group's approach is teamwork, working closely as colleagues in Western and Central Europe. The group has complementary expertise in pharmaceutical, biotechnology, medical device, diagnostic and related areas, so can offer pan-European and local, national advice and assistance to the Life Sciences und Healthcare industries.

The group is recognised as having centres of excellence in respect of pharmaceuticals and medical devices in its practices in the United Kingdom, the Netherlands and Germany as well as specialist tax expertise in France.

Services

The CMS Life Sciences und Healthcare Sector Group provides the following comprehensive range of services:

  • Regulatory
  • Pre-clinical and clinical research
  • Collaboration and licensing
  • Financing/M&A stock option schemes
  • Business restructuring
  • Strategic alliances, mergers and acquisitions
  • Distribution and parallel import issues
  • Patent protection and enforcement
  • Branding, trade dress, advertising and labelling
  • Media issues
  • Personal data
  • Product liability and litigation
  • Health and safety
  • EC & competition/competition enforcement
  • Public sector tendering
  • Environment
  • Immigration

Contact

For further information on CMS Life Sciences und Healthcare Sector Group please contact Mr. Jens Wagner.

We are strategic partners of

Young Excellence in healthcare

Young Excellence in Healthcare (YEH) is an interdisciplinary network bringing together young professionals from the healthcare sector. It seeks to develop an intelligent framework for delivering health services in the world of tomorrow. CMS Germany advises YEH strategically and exclusively on all legal matters. CMS also acts as a sounding board for the legal issues and healthcare policies YEH wishes to promote.

Read more Read less

Law Firm of the Year for Healthcare

JUVE Guide, 2018/2019

Choose area

    Care Market

    As the population in Germany ages, care and retirement homes are one of the fastest-growing sectors in the country. As such, they are attracting increasing attention from investors. A major factor here is that demand for care services is largely independent of the economic cycle. The high potential for consolidation in the sector is also a powerful driver: investment in social welfare facilities offers attractive prospects.

    Read more

    Healthcare

    The healthcare sector in Germany is heavily regulated, shaped by a number of very different interests and, above all, subject to constant change. Demographic change is an additional factor – an aging population is increasing the demand for medical services. Players in the healthcare market need to take advantage of existing opportunities, minimise the risks and avoid undesirable developments.

    Read more

    Feed

    Show only
    05 Dec 19
    A leg­al roadmap for Can­nabis 2019
    17 Jan 20
    New guid­ance on cy­ber­se­cur­ity for med­ic­al devices pub­lished
    In Decem­ber 2019, the Med­ic­al Device Co­ordin­a­tion Group (“MD­CG”) is­sued a new guid­ance to help med­ic­al device man­u­fac­tur­ers meet the cy­ber­se­cur­ity re­quire­ments in the Med­ic­al Devices Reg­u­la­tion (“MDR”)...
    26 Nov 19
    Fu­ture fa­cing life sci­ence and health­care: A wealth...
    15 Jan 20
    Can newly dis­covered can­nabis com­pounds be pro­tec­ted by pat­ents?
    A break­through dis­cov­ery has re­cently hit the news: tet­rahy­drocan­nabi­phorol (THCP) and can­na­bid­i­phorol (CB­DP), two new can­nabin­oid com­pounds, have been dis­covered in Can­nabis sativa and char­ac­ter­ised...
    October 2019
    Health­care M&A
    Get­ting the Deal Through
    23 Dec 19
    So­cial Me­dia and mHealth Data EMA / HMA Re­port
    New and in­nov­at­ive tech­no­lo­gies have led to a huge in­crease in data com­ing from sources that haven’t pre­vi­ously been used with­in the reg­u­lated medi­cines in­dustry. In re­cog­ni­tion of this ex­plo­sion of...
    September 2019
    CMS Life Sci­ences & Health­care Glob­al Bro­chure
    15 Nov 19
    Brexit and data pro­tec­tion: what to do next (when you don’t know what’s...
    Whilst the threat of a no-deal Brexit has been aver­ted for now, the fu­ture is by no means cer­tain. We have high­lighted some of the key is­sues for UK-based or­gan­isa­tions, and the EEA or­gan­isa­tions that...
    August 2019
    Dop­ing is dam­aging es­ports
    05 Nov 19
    Whis­tleblow­ing Dir­ect­ive ad­op­ted by the EU Coun­cil
    On 7 Oc­to­ber 2019, the EU Coun­cil ap­proved the word­ing of the "Dir­ect­ive of the European Par­lia­ment and of the Coun­cil on the pro­tec­tion of per­sons who re­port breaches of Uni­on law", also known as the...
    25 June 2019
    AI in Life Sci­ences
    Leg­al per­spect­ives on the op­por­tun­it­ies and chal­lenges...
    03 Oct 19
    In­ter­im meas­ures in Main­land Chinese courts in aid of Hong Kong-seated...
    On 1 Oc­to­ber 2019, the Ar­range­ment Con­cern­ing Mu­tu­al As­sist­ance in Court-ordered In­ter­im Meas­ures in Aid of Ar­bit­ral Pro­ceed­ings (the “Ar­range­ment”), con­cluded between China’s Su­preme People’s...